Missouri’s attorney general issues a cease-and-desist warning to Eli Lilly over a requirement that hospitals provide claims-level data to qualify for statutory 340B drug discounts. The policy draws further pushback as additional hospitals challenge it in court, according to coverage of the dispute.
Outlets describe the dispute as part of a wider trend of state scrutiny of 340B-related data demands by drugmakers. While the focus remains on Missouri’s action—warning Lilly to stop requiring hospitals to submit claims data—reports also note that the conflict is generating legal challenges from participating hospitals. Across the coverage, the emphasis varies between the legal steps taken by the attorney general and the ongoing litigation by hospitals, reflecting how different actors are contesting the data requirement.
Overall, the reporting frames the fight around whether Lilly can condition 340B discount eligibility on claims-data submission, with Missouri taking enforcement action and hospitals pursuing lawsuits. The story signals possible ripple effects as other states watch how the policy is handled.
